How Long Do Type 1 Diabetics Live Today?

People with type 1 diabetes today can expect to live well into their 60s and 70s, though on average they still face a life expectancy gap compared with the general population. Swedish registry data from the late 2000s put the remaining life expectancy of a 20-year-old man with type 1 diabetes at roughly 50 additional years, meaning he could expect to live to about 70. But that average obscures enormous variation: depending on how well a person manages key risk factors, the range spans more than two decades in either direction. Understanding what drives that variation is where the picture gets interesting.

What the Numbers Look Like Right Now

The most detailed modern estimate comes from a Finnish-Swedish analysis that built a life expectancy table from actual clinical data. For 20-year-old men with type 1 diabetes, remaining life expectancy ranged from about 29 additional years to nearly 51 additional years, a gap of more than 21 years between those with the worst and best risk-factor profiles. For women the same age, the range was about 35 to 54 additional years, an 18.9-year spread.¹ Swedish national data from 2007 to 2011 showed that a 20-year-old man with type 1 diabetes could expect about 50 more years of life, while a 20-year-old woman could expect about 52 more.²

Those figures come from countries with universal healthcare and excellent diabetes registries. They represent what is achievable with modern medicine, reliable access to insulin and supplies, and consistent medical follow-up. They do not represent every person with type 1 diabetes worldwide, a distinction that matters enormously.

How Far Things Have Come

The gains over the past several decades have been dramatic. A landmark study from Pittsburgh compared people diagnosed with type 1 diabetes between 1950 and 1964 to those diagnosed between 1965 and 1980. The later group had a life expectancy at birth roughly 15 years longer, jumping from about 53 years to nearly 69 years.³ That improvement held regardless of sex or whether the person was diagnosed before or after puberty. Finnish data from the same era through more recent decades confirmed the pattern, showing improved survival curves across the entire study period.⁴

What drove these improvements? Better insulin formulations, the introduction of home blood glucose monitoring in the 1980s, the development of insulin pumps, and a shift toward tighter blood sugar targets all played roles. Before insulin’s discovery in the 1920s, type 1 diabetes was essentially a death sentence within months to a couple of years. The fact that we are now talking about life expectancies approaching 70 or beyond represents one of the more remarkable transformations in modern medicine.

Blood Sugar Control Is the Single Biggest Lever

The evidence on this point is about as strong as it gets in chronic disease research. The Diabetes Control and Complications Trial, launched in the 1980s, randomly assigned people with type 1 diabetes to either intensive blood sugar management or conventional treatment, then followed them for decades. The intensive group, which kept blood sugar levels significantly lower, had about a third lower rate of death compared with the conventional group over the long term.⁵ The original trial results, published by JAMA, showed 43 deaths in the intensive group versus 64 in the conventional group, a roughly 33% reduction in the risk of dying.⁶

Perhaps the most striking finding from that trial: the mortality rate in the intensive therapy group was not meaningfully different from the general U.S. population. Their standardized mortality ratio came in at 0.88, which essentially means they were dying at about the same rate as everyone else. The conventional therapy group, by contrast, had a mortality rate about 31% higher than the general population. And the risk climbed steeply with higher average blood sugar levels, especially for women above an HbA1c of 9%.⁷

The take-home message is clear: people with type 1 diabetes who maintain tight blood sugar control can approach the same lifespan as people without the condition. That is a remarkable statement, and it holds up across multiple analyses of the same cohort. The challenge, of course, is that achieving and sustaining that level of control is extremely demanding, requiring constant monitoring, dose adjustments, and vigilance against both highs and dangerous lows.

What Actually Kills People With Type 1 Diabetes

The leading causes of death shift dramatically depending on how long a person has lived with the disease. In the first decade after diagnosis, the primary threat is acute diabetes complications like diabetic ketoacidosis and severe low blood sugar episodes, which account for nearly three-quarters of deaths in that window. Between years 10 and 20, the picture diversifies: cardiovascular disease, kidney disease, and infections each claim a roughly equal share. After 20 years with the condition, chronic complications dominate, with cardiovascular disease alone responsible for about 40% of all deaths.⁸

Severe low blood sugar episodes deserve special attention. They are common in type 1 diabetes, and estimates suggest that somewhere between 4 and 10 percent of people with the condition ultimately die from hypoglycemia. This includes some cases of so-called “dead in bed” syndrome, in which a young person with type 1 diabetes is found dead in the morning with no other apparent cause.⁹ These deaths are a reminder that the danger in type 1 diabetes is not just chronically elevated blood sugar but also the risk that comes from trying to keep it low.

The Cardiovascular Problem

Heart disease is the biggest long-term killer, and the relationship with blood sugar is quantifiable. For each percentage point increase in average HbA1c, the risk of a major cardiovascular event rises by roughly 42%. Blood sugar is the second most important risk factor after age itself, outweighing traditional cardiovascular risk factors like cholesterol levels or blood pressure in this population.¹⁰

What makes cardiovascular disease in type 1 diabetes particularly insidious is that it tends to develop earlier in life than in the general population. People with type 1 diabetes carry a reduction in life expectancy of at least 11 years attributable to cardiovascular causes, and those diagnosed young face a substantially higher risk. The mechanisms go beyond just high blood sugar: chronic hyperglycemia triggers inflammation in blood vessel walls, promotes the attachment of immune cells to artery linings, and causes arteries to thicken. Even people with well-controlled blood sugar and no other traditional risk factors still carry elevated cardiovascular risk, suggesting that something about the disease itself, possibly immune system dysfunction related to the underlying autoimmune process, contributes independently to atherosclerosis.¹¹

The Kidney Connection

Kidney disease has long been one of the most feared complications of type 1 diabetes, and its presence dramatically changes the survival calculus. Data from a study tracking people with type 1 diabetes and diabetic nephropathy showed that the crude mortality rate per 100 person-years was 2.4 for those with kidney disease alone, but jumped to 7.2 in those who had progressed to kidney failure, 9.2 in those with cardiovascular disease, and 18.7 in those with both kidney failure and cardiovascular disease.¹² Kidney disease and heart disease feed each other in a vicious cycle.

A Scottish study looking at life expectancy in type 1 diabetes found that kidney disease was strongly linked to shorter survival, with death rates greatly elevated in those with worse kidney function. But here is the catch: even people with type 1 diabetes who had perfectly preserved kidney function still had a substantial life expectancy gap compared with the general population. Eliminating kidney disease entirely would narrow the gap but would not close it.¹³ This reinforces the idea that cardiovascular and other risks continue to chip away at survival independently of kidney complications.

Women Face a Steeper Penalty

One of the more troubling findings in type 1 diabetes research is the gender gap in excess mortality. A systematic review pooling data from 26 studies found that women with type 1 diabetes have about a 40% greater excess risk of dying from any cause compared with men with the condition. For vascular events, the disparity is even wider: women face roughly twice the excess risk of fatal cardiovascular disease and about two and a half times the excess risk of coronary heart disease compared with men, after accounting for the baseline differences in risk between the sexes. The gap showed up for stroke and kidney-related deaths as well, though not for cancer or accidental death.¹⁴

This does not mean women with type 1 diabetes die younger than men with the condition in absolute terms. The absolute life expectancy numbers from Sweden actually show women living slightly longer. What the excess risk comparison captures is something different: compared with women in the general population, women with type 1 diabetes lose more years of life than men with type 1 diabetes lose relative to men in the general population. The protective cardiovascular advantage that women normally enjoy appears to be eroded more severely by diabetes. The reasons are not fully understood but likely involve hormonal interactions, differences in how blood vessel inflammation develops, and possibly differences in treatment patterns.

Income, Education, and Geography

Where you live and how much you earn can matter as much as your blood sugar control. A systematic review found that regardless of the type of healthcare system, lower socioeconomic status was consistently and independently linked to both higher death rates and more complications in adults with type 1 diabetes.¹⁵ Swedish data put numbers to this: people in the two lowest income groups had roughly twice the risk of heart disease and about three times the risk of death compared with those in the highest income group.¹⁶ A New Zealand study estimated that about a quarter of all deaths and more than half of cardiovascular deaths among people with type 1 diabetes in their cohort could be attributed to socioeconomic inequality.¹⁷

The global picture is even starker. A 2022 modeling study estimated that a 10-year-old diagnosed with type 1 diabetes in a high-income country could expect about 65 more years of life. The same child in a low-income country could expect only 13.¹⁸ That fivefold gap reflects differences in insulin availability, access to monitoring technology, healthcare infrastructure, and the ability to manage complications before they become fatal. In many parts of sub-Saharan Africa and South Asia, type 1 diabetes remains a disease that cuts life dramatically short, not because we lack the knowledge to treat it but because the tools are not reaching the people who need them.

How Technology Is Shifting the Curve

Continuous glucose monitors and automated insulin delivery systems represent the biggest technological shift in type 1 diabetes management since the insulin pump. A nationwide cohort study of adults with type 1 diabetes found that those using continuous glucose monitors had dramatically lower rates of serious complications: about 60% lower rates of diabetic ketoacidosis, roughly 57% lower rates of end-stage kidney disease, about 72% lower rates of cardiovascular disease, and approximately 62% lower mortality compared with non-users.¹⁹

Those are observational numbers, not randomized trial results, so some of the benefit likely reflects the fact that people who adopt new technology tend to be more engaged with their health in general. Still, the magnitude of the associations is hard to dismiss, and it aligns with what we know about blood sugar variability and complication risk. Health economic modeling of advanced hybrid closed-loop systems, which automatically adjust insulin delivery based on sensor readings, estimated that these devices could add about 0.16 years of life expectancy and nearly 2 quality-adjusted life years over a person’s lifetime, primarily by reducing and delaying complications.²⁰ The practical reality is that these technologies reduce the cognitive and emotional burden of constant self-management, which may matter as much for long-term outcomes as the glucose data itself.

People Who Live Decades Without Complications

Among the most intriguing findings in type 1 diabetes research is that a subset of people survives well into old age with few or no serious complications, despite having had the disease for 50 years or more. The Joslin Diabetes Center has studied these individuals, known as “Medalists,” to understand what protects them. The absence of kidney disease after 15 to 20 years of diabetes appears to be one of the strongest markers of long-term survival. High levels of HDL cholesterol are positively linked with longevity in this group. A family history of long life and the absence of type 2 diabetes or high blood pressure in the family also seem to matter, suggesting a genetic component to resilience.²¹

Good blood sugar control alone does not fully explain why these people avoid catastrophic complications. Laboratory work on cells from Medalists who remained complication-free found that they had enhanced DNA damage repair pathways compared with those who developed complications. Their cells were better at fixing the molecular damage that high blood sugar inflicts, and they showed lower levels of inflammation.²² This suggests that some people are biologically wired to tolerate the metabolic stress of type 1 diabetes better than others, independent of how carefully they manage their blood sugar. It also opens up the possibility that future therapies could target those protective pathways.

Autoimmune Companions and Overlooked Risks

Type 1 diabetes is an autoimmune disease, and autoimmune conditions tend to cluster. Thyroid disease and celiac disease are the most common companions. The effect on outcomes is more nuanced than you might expect. A population-based study of young people with type 1 diabetes found that having an additional autoimmune disease on top of diabetes had no statistically significant effect on either blood sugar control or mortality risk.²³ A Mediterranean cohort found that those with only thyroid autoimmune disease actually had lower odds of peripheral artery disease and kidney disease, while those with other autoimmune conditions had higher odds of ischemic heart disease.²⁴

Celiac disease presents a different wrinkle. A study following people with both type 1 diabetes and celiac disease found that during the first five years after the celiac diagnosis, there was no added mortality risk. But the risk climbed with time: after 15 or more years of living with both conditions, the hazard ratio for death was 2.8, meaning nearly triple the risk compared with having type 1 diabetes alone.²⁵ The reasons are not entirely clear, but chronic intestinal inflammation, nutrient malabsorption, and the difficulty of managing two demanding dietary conditions simultaneously likely all contribute.

The Weight Problem Nobody Talks About

Historically, type 1 diabetes was associated with leanness, but that has changed. Rising rates of overweight and obesity among people with type 1 diabetes have created a phenomenon sometimes called “double diabetes,” where a person has the autoimmune insulin deficiency of type 1 alongside the insulin resistance typically associated with type 2. This combination is linked with increased risk of both small-vessel and large-vessel complications and higher mortality.²⁶ The intensive insulin therapy that has done so much to improve survival also promotes weight gain, creating a trade-off that clinicians and patients have to navigate carefully.

Physical activity appears to help, though the data is less definitive than you might expect. A large European study of people with type 1 diabetes found that participating in moderate or vigorous physical activity at least once a week was associated with about a third lower risk of dying, though the association was borderline in statistical terms.²⁷ Exercise in type 1 diabetes is genuinely complicated: it can cause unpredictable blood sugar swings, and the fear of low blood sugar during or after activity is a real barrier. But the cardiovascular and metabolic benefits make it one of the few modifiable factors beyond blood sugar control that can potentially move the needle on long-term survival.

Mental Health and Insulin Omission

One rarely discussed threat to longevity in type 1 diabetes is the deliberate omission of insulin as a form of weight control. Because skipping or reducing insulin doses causes the body to shed calories through urine, some people with type 1 diabetes, particularly adolescents and young adults, use this as a purging behavior. Eating disorders are more common in the type 1 diabetes population, and insulin omission is a unique and dangerous behavior available only to people who depend on insulin. It leads to chronically high blood sugar, accelerated complications, and increased mortality.²⁸ This is a distinctly human dimension of the disease that does not show up in population-level statistics but is well recognized by clinicians who work with young people with type 1 diabetes.

The psychological burden of living with a condition that demands constant attention, every single day, for an entire lifetime, has consequences that compound over decades. Burnout, depression, and diabetes distress are common and can directly erode the self-management behaviors that keep people alive. Any honest conversation about life expectancy in type 1 diabetes has to reckon with the fact that the tools exist to live a long life, but the human cost of wielding those tools relentlessly can itself become a threat.